Novozymes A/S

SWX:NZYMB Stock Report

Market Cap: CHF25.0b

Novozymes Valuation

Is NZYMB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NZYMB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NZYMB (CHF45.21) is trading above our estimate of fair value (CHF35.28)

Significantly Below Fair Value: NZYMB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NZYMB?

Other financial metrics that can be useful for relative valuation.

NZYMB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.1x
Enterprise Value/EBITDA35.3x
PEG Ratio3.6x

Price to Earnings Ratio vs Peers

How does NZYMB's PE Ratio compare to its peers?

The above table shows the PE ratio for NZYMB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.7x
EMSN EMS-CHEMIE HOLDING
37.8x6.4%CHF17.3b
GIVN Givaudan
41.2x7.7%CHF36.8b
SIKA Sika
40.7x12.5%CHF43.2b
CLN Clariant
27.2x22.7%CHF4.6b
NZYMB Novozymes
63.3x17.5%CHF180.9b

Price-To-Earnings vs Peers: NZYMB is expensive based on its Price-To-Earnings Ratio (63.3x) compared to the peer average (36.4x).

Price to Earnings Ratio vs Industry

How does NZYMB's PE Ratio compare vs other companies in the European Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.2%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.2%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: NZYMB is expensive based on its Price-To-Earnings Ratio (63.3x) compared to the European Chemicals industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is NZYMB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NZYMB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio63.3x
Fair PE Ratio29.5x

Price-To-Earnings vs Fair Ratio: NZYMB is expensive based on its Price-To-Earnings Ratio (63.3x) compared to the estimated Fair Price-To-Earnings Ratio (29.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NZYMB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF45.21
CHF56.56
+25.1%
9.4%CHF65.31CHF45.72n/a14
Apr ’25CHF45.21
CHF54.75
+21.1%
9.6%CHF65.22CHF44.35n/a14
Mar ’25CHF45.21
CHF52.23
+15.5%
8.5%CHF58.85CHF41.70n/a14
Feb ’25CHF45.21
CHF49.71
+9.9%
8.2%CHF56.29CHF40.78n/a13
Jan ’25CHF45.21
CHF49.00
+8.4%
8.1%CHF54.50CHF41.32n/a13
Dec ’24CHF45.21
CHF48.73
+7.8%
9.0%CHF55.65CHF42.19n/a13
Nov ’24CHF45.21
CHF46.39
+2.6%
11.9%CHF55.14CHF35.26n/a13
Oct ’24CHF45.21
CHF48.45
+7.2%
12.6%CHF59.59CHF35.63n/a13
Sep ’24CHF45.21
CHF47.83
+5.8%
11.4%CHF58.94CHF38.44n/a14
Aug ’24CHF45.21
CHF50.05
+10.7%
11.3%CHF59.71CHF38.94n/a14
Jul ’24CHF45.21
CHF51.75
+14.5%
13.4%CHF68.39CHF39.46n/a14
Jun ’24CHF45.21
CHF51.81
+14.6%
12.6%CHF67.97CHF41.83n/a14
May ’24CHF45.21
CHF52.32
+15.7%
12.2%CHF67.44CHF42.32CHF45.2114
Apr ’24CHF45.20
CHF51.88
+14.8%
12.8%CHF68.26CHF42.83CHF45.2114
Mar ’24CHF45.20
CHF51.99
+15.0%
13.5%CHF68.98CHF42.45CHF45.2114
Feb ’24CHF45.20
CHF52.84
+16.9%
13.8%CHF69.79CHF42.95CHF45.2114
Jan ’24CHF45.20
CHF55.20
+22.1%
13.4%CHF69.04CHF43.81CHF45.2115
Dec ’23CHF45.20
CHF54.15
+19.8%
15.1%CHF71.28CHF43.56CHF45.2116
Nov ’23CHF45.20
CHF56.28
+24.5%
14.8%CHF71.68CHF43.81CHF45.2116
Oct ’23CHF45.20
CHF58.04
+28.4%
15.6%CHF72.83CHF42.92CHF45.2116
Sep ’23CHF45.20
CHF61.14
+35.3%
15.5%CHF73.52CHF45.95CHF45.2116
Aug ’23CHF45.20
CHF59.95
+32.6%
17.1%CHF73.76CHF45.19CHF45.2117
Jul ’23CHF45.20
CHF63.53
+40.6%
16.5%CHF79.89CHF48.42CHF45.2118
Jun ’23CHF45.20
CHF65.53
+45.0%
16.8%CHF82.02CHF49.71CHF45.2118
May ’23CHF45.20
CHF64.74
+43.2%
16.1%CHF81.50CHF49.39CHF45.2118

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.